A009420 logo

Hanall Biopharma Co., Ltd. Stock Price

KOSE:A009420 Community·₩2.8t Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

A009420 Share Price Performance

₩0
-28050.00 (-100.00%)
₩0
-28050.00 (-100.00%)
Price ₩0

A009420 Community Narratives

There are no narratives available yet.

Trending Discussion

No trending discussion available.

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Moderate growth potential with mediocre balance sheet.

1 Risk
1 Reward

Hanall Biopharma Co., Ltd. Key Details

₩159.1b

Revenue

₩76.2b

Cost of Revenue

₩82.9b

Gross Profit

₩88.0b

Other Expenses

-₩5.1b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-99.95
52.11%
-3.19%
26.6%
View Full Analysis

About A009420

Founded
1973
Employees
304
CEO
Seung-Kook Park
WebsiteView website
www.hanall.co.kr

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson’s disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves’ disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.

Recent A009420 News & Updates

Recent updates

No updates

Hanall Biopharma Co., Ltd. Competitors